Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Stoekenbroek

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Nature Reviews. Cardiology|June 21, 2017
Dyslipidaemia: Statin-associated muscle symptoms - really all in the mind?Robert M Stoekenbroek, John J P Kastelein
Current Opinion in Cardiology|March 22, 2018
Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trialsRobert M Stoekenbroek, John J P Kastelein
European Journal of Pharmacology|May 20, 2015
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemiaRutger Verbeek, Robert M Stoekenbroek, G Kees Hovingh
Surgical Technology International|April 5, 2014
Systemic wound care: a meta-review of cochrane systematic reviewsDirk T Ubbink, Trientje B Santema, Robert M Stoekenbroek
BMC Medicine|October 13, 2015
PCSK9 inhibition: the way forward in the treatment of dyslipidemiaRobert M Stoekenbroek, John J P Kastelein, Roeland Huijgen
European Heart Journal|October 12, 2017
Homozygous familial hypercholesterolaemia: light at the end of the tunnelRobert M Stoekenbroek, G Kees Hovingh, John J P Kastelein
Nature Reviews. Endocrinology|October 28, 2018
Inhibiting PCSK9 - biology beyond LDL controlRobert M Stoekenbroek, Gilles Lambert, Bertrand Cariou, et al.
European Heart Journal|April 27, 2017
Can we afford not to screen for FH?Robert M Stoekenbroek, John J P Kastelein, G Kees Hovingh
Current Opinion in Lipidology|November 5, 2013
Recent failures in antiatherosclerotic drug development: examples from the thyroxin receptor agonist, the secretory phospholipase A2 antagonist, and the acyl coenzyme A: cholesterol acyltransferase inhibitor programsRobert M Stoekenbroek, John J P Kastelein, G Kees Hovingh
Future Cardiology|October 31, 2018
Inclisiran for the treatment of cardiovascular disease: the ORION clinical development programRobert M Stoekenbroek, David Kallend, Peter Lj Wijngaard, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Nature Reviews. Cardiology|June 21, 2017
Dyslipidaemia: Statin-associated muscle symptoms - really all in the mind?Robert M Stoekenbroek, John J P Kastelein
Current Opinion in Cardiology|March 22, 2018
Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trialsRobert M Stoekenbroek, John J P Kastelein
European Journal of Pharmacology|May 20, 2015
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemiaRutger Verbeek, Robert M Stoekenbroek, G Kees Hovingh
Surgical Technology International|April 5, 2014
Systemic wound care: a meta-review of cochrane systematic reviewsDirk T Ubbink, Trientje B Santema, Robert M Stoekenbroek
BMC Medicine|October 13, 2015
PCSK9 inhibition: the way forward in the treatment of dyslipidemiaRobert M Stoekenbroek, John J P Kastelein, Roeland Huijgen
European Heart Journal|October 12, 2017
Homozygous familial hypercholesterolaemia: light at the end of the tunnelRobert M Stoekenbroek, G Kees Hovingh, John J P Kastelein
Nature Reviews. Endocrinology|October 28, 2018
Inhibiting PCSK9 - biology beyond LDL controlRobert M Stoekenbroek, Gilles Lambert, Bertrand Cariou, et al.
European Heart Journal|April 27, 2017
Can we afford not to screen for FH?Robert M Stoekenbroek, John J P Kastelein, G Kees Hovingh
Current Opinion in Lipidology|November 5, 2013
Recent failures in antiatherosclerotic drug development: examples from the thyroxin receptor agonist, the secretory phospholipase A2 antagonist, and the acyl coenzyme A: cholesterol acyltransferase inhibitor programsRobert M Stoekenbroek, John J P Kastelein, G Kees Hovingh
Future Cardiology|October 31, 2018
Inclisiran for the treatment of cardiovascular disease: the ORION clinical development programRobert M Stoekenbroek, David Kallend, Peter Lj Wijngaard, et al.
Pageof 3